Entrada jumped over 30% in morning trading,above its IPO price at 20 dollars per share
Entrada jumped over 30% in morning trading,above its IPO price at 20 dollars per share.Entrada, which is working to develop therapeutics for rare neuromuscular diseases such as Duchenne muscular dystrophy and myotonic dystrophy type 1, said it believes the proceeds, coupled with its existing resources, will be sufficient to fund its operating expenses and capital-spending needs into the second quarter of 2024.